Class 4 caution in use-Rosuvastatin 20mg & 40mg Sandoz

Sandoz Ltd. has informed the MHRA that there is missing safety information in the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) for Rosuvastatin 20mg and 40mg Tablets.

MHRA Drug alert date: 1st October 2024

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-sandoz-ltd-dot-rosuvastatin-20mg-40mg-tablets-el-24-a-slash-45

This is a caution in use only we are not accepting stock returns

Further Information

For medical information queries, please contact: sandozgb@EU.propharmagroup.com, Telephone: +44 1276 698 101.

For stock control queries, please contact: sales.sandoz-gb@sandoz.com, Telephone: +44 1276 698607.